Valuation: Genome & Company

Market Cap 169B 116M 102M 94.41M 86.64M 163M 11.13B 165M 1.12B 438M 5.47B 434M 425M 18.92B P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 151B 103M 90.78M 84.42M 77.47M 146M 9.95B 148M 1B 392M 4.89B 388M 380M 16.92B EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
82.97%
Yield 2024 *
-
Yield 2025 -
Apr. 13 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
Apr. 02 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
Mar. 12 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
25-09-21 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
25-08-20 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
25-07-10 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
25-04-27 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
25-04-23 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
25-04-23 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
24-07-18 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-07-16 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24-01-24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day-8.91%
1 week+2.90%
Current month-3.37%
1 month-5.93%
3 months-38.85%
6 months-62.59%
Current year-45.78%
1 week 3,320
Extreme 3320
4,225
1 month 3,320
Extreme 3320
4,545
Current year 3,320
Extreme 3320
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 2015-09-23
Chief Executive Officer 55 2015-09-23
Director TitleAgeSince
Director/Board Member 55 2015-09-23
Director/Board Member 62 -
Director/Board Member 62 2025-03-27
Date Insider Type Main position Quantity % Market Cap.
5/9/25 Free

Director

40,000 0.1287%
5/9/25 Don

Chief Executive Officer

100,000 0.3217%
5/9/25 Free 10,000 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
-8.91%+2.90%+31.34%-44.94% 116M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.69%+1.46%+51.98%+89.62% 24.54B
Weighted average by Cap. +0.47%+0.92%+74.39%+136.18%

Financials

2024 2025
Net sales 27.74B 19M 16.69M 15.52M 14.24M 26.76M 1.83B 27.17M 184M 71.99M 899M 71.32M 69.78M 3.11B 24.59B 16.84M 14.79M 13.75M 12.62M 23.71M 1.62B 24.08M 163M 63.8M 797M 63.2M 61.84M 2.76B
Net income -20.11B -13.77M -12.1M -11.25M -10.32M -19.4M -1.33B -19.69M -134M -52.19M -652M -51.7M -50.59M -2.25B -6.43B -4.4M -3.87M -3.6M -3.3M -6.2M -424M -6.29M -42.69M -16.68M -208M -16.52M -16.17M -721M
Net Debt -48.91B -33.49M -29.41M -27.35M -25.1M -47.16M -3.23B -47.89M -325M -127M -1.59B -126M -123M -5.48B -17.86B -12.23M -10.74M -9.99M -9.17M -17.23M -1.18B -17.49M -119M -46.35M -579M -45.92M -44.93M -2B
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
26-07-24 ₩3,730.00 -8.91% 266,975
26-07-23 ₩4,095.00 +6.36% 346,206
26-07-22 ₩3,850.00 +8.76% 267,352
26-07-21 ₩3,540.00 +1.72% 284,528
26-07-20 ₩3,480.00 -4.00% 162,711
  1. Stock Market
  2. Stocks
  3. A314130 Stock